classieal studies indicate one of the pharmacological methods by which receptor specificity is defined, i.e., determination of potency series of agonists. He found that for certain responses, isoproterenol was most potent, followed by epinephrine, with norepinephrine considerably less active. The receptors mediating such responses (vascular dilatation, myocardial contractility, etc.) were termed /8adrenergic receptors. Another group of responses (vasoconstriction, stimulation of uterine contractility, etc.) were greater to 1-epinephrine and norepinephrine with a very weak response to isoproterenol. The receptors controlling these responses were called a-adrenergic receptors.
Subsequently antagonist drugs were developed which specifically blocked either the a (phentolamine, phenoxybenzamine) or the /34 (DCI, propranolol) group of receptors. The antagonists also provided an alternate method of characterizing adrenergic receptors. Thus a response was a if blocked by phentolamine, /3 if blocked by propranolol or DCI.
That drug receptors with similar affinities and specificities are present in a number of different tissues is of great clinical significance. Thus, when one administers isoproterenol to a patient with cardiogenic shock in the hope of stimulating myocardial contractility, he must be prepared for tachycardia, arrhythmias and profound and widespread vasodilatation that often accompany the desired response. Beta-adrenergic receptors are present not only throughout the heart (where they mediate effects on rate and contractility) but also in other areas of the vasculature. Similarly, if the /3-adrenergic blocking drug propranolol is given for its antiarrhythmic effects to an asthmatic patient, disconcerting bronchoconstriction may result. This is due to coincident blockade of f8-adrenergic receptors in bronchial smooth muscle. How much simpler these therapeutic problems would be if distinct adrenergic receptors with unique specificities were present in each tissue. Such a situation would mean that drugs could be designed to maximize stimulation or blockade of adrenergic receptors in one tissue while having minimal or no effect on receptors in other tissues.
In recent years, a growing body of experimental evidence has suggested that distinct subpopulations of /3-adrenergie receptors are present in different tissues. (table 1) Lands et al.5 were among the first to note this. A series of adrenergic agonists was compared for its effects on several responses generally considered to be mediated by /8-adrenergic receptors. Whereas effects on lipolysis and cardiac stimulation were closely correlated, those on bronchodilatation and vasodepression seemed to follow a different pattern. For example, l-norepinephrine was relatively potent at /3-receptors in the former group (termed /81 receptors) and quite ineffective at receptors in the latter tissues (/,2 receptors).
Subsequent investigations have revealed that the receptors of uterine6 tissue, as well as those which mediate glycogenolytic effects in liver and muscle generally, conform to the 82 subtype.7
That different classes of receptors exist has been confirmed in studies using several new /8adrenergic antagonists. These drugs selectively block receptors of one type more effectively than the other. For example, butoxamine appears to selectively antagonize effects mediated by 82 receptors8 whereas practolol is much more effective at sites.9 In addition, compounds have recently been synthesized which appear to selectively stimulate certain of the receptors. Soterenol and salbutamol,10 for example, compounds which lack the 2ring hydroxyl groups of catecholamines, appear selectively to activate the /32 receptors. The same is true of the catecholamine isoetharine5 which has an aliphatic substituent at the alpha carbon position.
These pharmacological differences among /3adrenergic receptors imply the existence of specific molecular differences in the receptor sites themselves. Differences between /81 and /82 adrenergic receptors are summarized in table 1. (A selective agonist or antagonist is one with relatively greater actions at 81 or /82 receptors whereas a nonselective drug is one with potent actions at both types of /3receptors. ) If these receptors can vary from organ to organ, is it possible that within those organs in which /8 receptors mediate more than one function, more than one type of ",/ receptor" might be present?
Specifically, for example, within the heart, could there be differences, albeit subtle, between those receptors mediating effects on contractility and those mediating effects on chronotropy and automaticity. Both of these would normally be classed as /31 receptors. Recently, a compound called dobutamine has been described which appears to augment ventricular contractility selectively with lesser effects on rate of beating.11 The development of this compound was the result of systematic studies of the effects of various catecholamines on cardiac contractility and automaticity." It was found that the /3-hydroxyl group seemed to contribute more to automaticity than to contractility. Thus a series of dopamine analogues, all lacking the /8-hydroxyl radical was tested. Dobutamine, which bears a large substituent on the amino nitrogen, was found to increase contractility more but automaticity less than isoproterenol. If these reports can be confirmed, they will provide further evidence for heterogeneity of /8 receptors within a single organ, the heart.
As yet, none of these selective agonist or antagonist drugs have become clinically available. Nonetheless, the clinical implications of selectivity in /8-adrenergic responses are great. Current evidence suggests that it may be possible to design drugs which can stimulate the heart without causing vasodepression or vasoconstriction, or /3 blockers which block sympathetic effects on the heart without exacerbating bronchospasm. Similarly, use of the selective /32 agonist isoetharine5 as an aeresol spray for asthma decreases the risks of tachycardia and cardiac arrhythmias which might otherwise accompany such therapy.
Of perhaps even greater utility would be drugs which could increase cardiac contractility (as in cardiogenic shock) without causing tachycardia or precipitating arrhythmias. As noted earlier, this may be possible. However, it should be pointed out that whereas the distinction between ,8, and ,/2 receptors is now based on a firm experimental foundation, conclusive evidence for differing types of receptors mediating inotropic and chronotropic effects of catecholamines in the heart has yet to be obtained.
Future experimental approaches to these problems are likely to proceed at both the physiological and the biochemical level. Receptor specificity will continue to be defined by analysis of potency series of new agonist and antagonist drugs on various tissue preparations, compared to standard drugs such as isoproterenol, norepinephrine, and propranolol.
At a biochemical level, potency of adrenergic agonists and antagonists on a specific enzyme system, adenylate cyclase, which produces the "2nd messenger," cAMP, often correlate closely with effects of these drugs on whole tissues.'2' 13 The order of potency of catecholamines in stimulating adenylate cyclase in such tissues as liver, heart, skeletal muscle, uterus, and several others invariably coincides with that of a typical beta receptor (i.e., isoproterenol > epinephrine > norepinephrine) and the stimulation of the enzyme by catecholamines is blocked by but not a-receptor antagon-Circuilation, Volumnte XLIX, May 1974 ists. 13 Thus it seems clear that in many cases, /3adrenergic receptors are functionally linked to adenylate cyclase.
It is not clear yet whether the subclassification of P,i and /82 adrenergic receptors will be equally applicable to the adenylate cyclase coupled /3 receptors, though several preliminary studies have suggested that this may in fact be the case.'2' 14 If it is, this system will provide a convenient in vitro assay tool for testing selectivity of newly developed /3-adrenergic agonist and antagonist drugs. The relationship, if any, of a-adrenergic receptors to adenylate cyclase is at the present time not well established. Although in several tissues a-adrenergic effects appear to involve a reduction in cAMP levels (e.g., in pancreatic islets or platelets) this phenomenon has not been generally demonstrlable in other tissues. '3 Ultimately the goal is to isolate and characterize the different types of adrenergic receptor molecules themselves, and to use the information obtained to design new compounds of greater specfficity and therapeutic utility. Although preliminary efforts in this direction have been made,15 current methods are still too unrefined to approach this goal. ROBERT J. LEFKOWITZ, M.D.
